Cristcot

-- Prescription Drug User Fee Act (PDUFA) target date of October 2026 -- -- Submission supported by CESSA Phase 3 trial results demonstrating statistically significant rates of clinical remission in patients with UC of the rectum -- -- If approved, ngHCA would be the first and only FDA-approved hy

-- Ms. Herman is a life sciences executive with extensive experience developing commercialization strategies and building commercial teams -- AUSTIN, Texas, May 6, 2026 -- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today

Cristcot will attend the J.P. Morgan Healthcare Conference in San Francisco, CA, and co-sponsor An Evening With Friends on Monday, January 12, 2026. The event will bring together leaders in the life sciences.

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts Next-generation Hydrocortisone Acetate (ngHCA) Suppository Administered with Sephure Suppository Applicator Demonstrates Statistically Significant Rates of Clinical Remission in Pa

Cristcot develops pharmaceutical formulations and drug-device systems to address challenges affecting patient adherence, caregiver confidence, and therapeutic outcomes.

Cristcot is a pharmaceutical development and research company that specializes in drug formulations and drug-device technologies intended to help patients and caregivers address obstacles in disease management.

The page states that using cristcot.com constitutes acceptance of its Privacy Policy.